International Immunology, Vol. 1, No. 5, pp. 551-554,November 1989
© 1989 Japanese Society for Immunology
other |
SP-40,40 is an inhibitor of C5b-6-initiated haemolysis
Department of Medicine, University of Melbourne and Renal Unit, St Vincent's Hospital Melbourne 3065, Australia
1 Department of Veterinary Preclinical Sciences, University of Melbourne Parkville 3052, Australia
2 Department of Nephrology, The Royal Melbourne Hospital Melbourne 3050, Australia
Correspondence to: Correspondence to Dr B. F. Murphy, Renal Unit, St Vincent's Hospital, Fitzroy, Victoria 3065. Australia
This study examines the function of SP-40,40, a newly identified component of the SC5b-9 complement complex, In the regulation of the terminal complement pathway. Purified SP-40,40 was shown to inhibit, in a dose-dependent manner, C5b-6-initiated haemolysls. Apparently additive inhibition was also demonstrated in conjunction with complement S-protein, although SP-40,40 appears to be the more potent inhibitor on an equimolar basis. The data suggest that SP-40,40, like S-protein, probably combines with the nascent C5b7 complex, forming a cytolytically inactive SC5b7-SP-40,40 complex. Preparations of S-protein, purified by an established technique, were shown to be contaminated with SP-40,40. Preparations of affinitypurified SP-40,40 were also shown to contain S-protein, suggesting that these proteins may be partially complexed in plasma.
Keywords: complement, C5b-9, S-protein, clusterin, SGP-2
Received 10 May 1989, accepted 17 July 1989.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  E. M. Pasini, M. Kirkegaard, P. Mortensen, H. U. Lutz, A. W. Thomas, and M. Mann In-depth analysis of the membrane and cytosolic proteome of red blood cells Blood, August 1, 2006; 108(3): 791 - 801. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C Jomary, G Chatelain, D Michel, A Weston, M. Neal, and S. Jones Effect of targeted expression of clusterin in photoreceptor cells on retinal development and differentiation J. Cell Sci., January 5, 1999; 112(10): 1455 - 1464. [Abstract] [PDF]
|
|
|
|
 |
|
 S. C. Makrides Therapeutic Inhibition of the Complement System Pharmacol. Rev., March 1, 1998; 50(1): 59 - 88. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. Moen, E. Fosse, E. Dregelid, V. Brockmeier, C. Andersson, K. Hogasen, P. Venge, T. E. Mollnes, and P. Kierulf Centrifugal Pump and Heparin Coating Improves Cardiopulmonary Bypass Biocompatibility Ann. Thorac. Surg., October 1, 1996; 62(4): 1134 - 1140. [Abstract] [Full Text]
|
|
|
|
 |
|
 O. Moen, E. Fosse, J. Braten, C. Andersson, K. Hogasen, T. Mollnes, P. Venge, and P. Kierulf Differences in blood activation related to roller/centrifugal pumps and heparin coated/uncoated surfaces in a cardiopulmonary bypass model circuit Perfusion, March 1, 1996; 11(2): 113 - 123. [Abstract] [PDF]
|
|
|
|
|
|
O. Moen, E. Fosse, V. Brockmeier, C. Andersson, T. E. Mollnes, K. Hogasen, and P. Venge Disparity in Blood Activation by Two Different Heparin-Coated Cardiopulmonary Bypass Systems Ann. Thorac. Surg., November 1, 1995; 60(5): 1317 - 1323. [Abstract] [Full Text]
|
|
|
|
 |
|
 M. Z. Kounnas, E. B. Loukinova, S. Stefansson, J. A. K. Harmony, B. H. Brewer, D. K. Strickland, and W. S. Argraves Identification of Glycoprotein 330 as an Endocytic Receptor for Apolipoprotein J/Clusterin J. Biol. Chem., June 2, 1995; 270(22): 13070 - 13075. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. L. McRae, P. J. Cowan, D. A. Power, K. I. Mitchelhill, B. E. Kemp, B. P. Morgan, and B. F. Murphy Human Factor H-related Protein 5 (FHR-5). A NEW COMPLEMENT-ASSOCIATED PROTEIN J. Biol. Chem., February 23, 2001; 276(9): 6747 - 6754. [Abstract] [Full Text] [PDF]
|
|